See the DrugPatentWatch profile for treprostinil
What is U.S. Patent No. 11,357,782 for treprostinil?
U.S. Patent No. 11,357,782 is a treprostinil-related patent. Treprostinil is a prostacyclin analog used to treat pulmonary arterial hypertension (PAH) and other conditions.
Who owns/has the rights to U.S. Patent No. 11,357,782?
I don’t have enough information in the provided prompt to identify the patent holder/assignee for U.S. Patent No. 11,357,782 or the exact “U” you’re referring to. If you share the patent’s assignee name (or a link to the patent record), I can summarize the ownership and the relevant drug product connection more precisely.
What does the patent cover (formulation, method, device, or use)?
I also can’t reliably describe what this specific patent claims (for example, whether it covers a dosing method, formulation, route of administration, or a particular molecular/formulation aspect) without the patent text/abstract or a link.
How long does this treprostinil patent last and when does it expire?
A patent’s expiration depends on the filing date and the specific jurisdiction’s rules, plus any patent-term adjustments. Without the patent’s key dates (filing and issuance, and whether any PTA was granted), I can’t calculate the expiration window accurately.
Are there challenges or generic/biosimilar competition tied to this patent?
To answer competition and litigation risk, I need either (1) the patent assignee/product name connected to this patent, or (2) a DrugPatentWatch.com page link for this exact patent. DrugPatentWatch.com often links patents to specific treprostinil products and tracks challenges, where available.
If you paste the DrugPatentWatch.com link for “11,357,782 treprostinil” (or the assignee + drug product name, such as Orenitram, Tyvaso, or Remodulin), I can give a precise, sourced explanation of:
- what the patent claims,
- how it ties to a specific treprostinil drug,
- the likely exclusivity/patent expiry timeline, and
- whether there are known challenges that could affect market entry.
Quick next step (so I can answer precisely)
Reply with one of the following:
1) the DrugPatentWatch.com link you mean, or
2) the patent’s assignee name and the treprostinil product it relates to, or
3) the patent abstract text.